B+
Bull case
25%
Probability
Target price
$0.68
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
BEAT
HeartBeamFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Positive ALIGN-ACS data, a workable pivotal-study pathway and a funded partner for the patch could validate the sharper clinical focus. The September strategy may conserve capital by avoiding a large arrhythmia sales build-out [#IR-2026-09-21] (shareholder letter).
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-11-05.
What can break
ALIGN-ACS is a pilot; clinical performance, pivotal-study requirements and the timing of any expanded indication remain uncertain.
Momentum
100
Value
36
Sentiment
32
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.40 · Bull $0.68 · Bear $0.16Analysis 2026-09-25; returns require an exact persisted reference.
Earnings
2026-11-05
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-30 • Vendor: Data Vendor v1
Scores
As of 2026-10-30 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-30
Investment thesis
As of 2026-10-30
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-30. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $3.50
Why
Momentum100 · Δ7d -
Value36 · Δ7d +0.1
Sentiment32 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-05.
- • Value remains the lead driver in the composite, 7D delta +0.1.
Contradictions & invalidation
- • ALIGN-ACS is a pilot; clinical performance, pivotal-study requirements and the timing of any expanded indication remain uncertain.
- • Current FDA clearance is for arrhythmia assessment, not myocardial infarction or ischemia [#IR-2026-09-21] (company indications in shareholder letter).
- • Heart-attack assessment remains unapproved, the pivotal study is not yet established, and limited commercialization reduces near-term revenue evidence.
Catalyst clock
2026-11-05
ALIGN-ACS results at TCT 2026
Lead driver: Value · See fundamentals
Momentum
100
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
36
47% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.1
Sentiment
32
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 99.9 / Value 36.4 / Sentiment 31.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.40
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.16
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-30
Fundamentals (TTM)
As of 2026-10-30
Market Cap
$30.99M
Beta
-0.79
Shares Out
56.35M
P/E (TTM) · Derived
-0.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.58
Rev YoY
-
EPS YoY
-35.0%
Gross Margin
-
Op Margin
-
Net Debt
-$4.38M
Current Ratio
3.66
As of 2026-10-30 • Updated nightlySource: Internal modelMethods & Data